| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 290.34 | 22.7% | 26.0% |
| Total Income | 294.96 | 22.1% | 25.9% |
| Expenditure | 380.89 | 2.1% | 4.7% |
| PBT | -93.01 | 1720.1% | 39.9% |
| Net Profit | -88.70 | 946.0% | 28.8% |
| OPM | 3.52% | 24.82pp | 51.02pp |
| NPM | -30.07% | 32.84pp | 12.77pp |
| EPS | 7.74 | 741.3% | 222.7% |
Onesource Specialty Pharma Ltd. Approves Q3 and Q4 2025 Financial Results
23 Jan 2026 · 23 Jan, 8:53 pm
Summary
Onesource Specialty Pharma Ltd. has approved the un-audited financial results for Q3 and Q4 2025. The company's revenue from operations stands at 2,902.20 million and 3,751.87 million for Q3 and Q4 respectively. The total income for the year ended December 31, 2025, is 13,172.71 million. The company's profit before tax for the year ended December 31, 2025, is 200.00 million.
Key Highlights
- 1
Revenue from operations for Q3 2025: 2,902.20 million
- 2
Revenue from operations for Q4 2025: 3,751.87 million
- 3
Total income for the year ended December 31, 2025: 13,172.71 million
- 4
Profit before tax for the year ended December 31, 2025: 200.00 million
Informational and educational content only. Not investment advice.